Table 2.
Association of clinical characteristics and pCR in univariate analysis
| N (%) | pCR/0 (ypT0, ypN0) N (%) | P value | pCR/is (ypT0/is, ypN0) N (%) | P value | |
|---|---|---|---|---|---|
| Histologic type | |||||
| Ductal | 179 (87.3) | 44 (24.6) | 0.76 | 86 (48.0) | 0.36 |
| Lobular | 12 (5.9) | 4 (33.3) | 6 (50.0) | ||
| Others | 14 (6.8) | 3 (21.4) | 4 (28.6) | ||
| Clinical T | |||||
| T1–T2 | 119 (58.0) | 34 (28.6) | 0.84 | 61 (51.3) | 0.37 |
| T3–T4 | 59 (28.8) | 16 (27.1) | 26 (44.1) | ||
| Unknown^ | 27 (13.2) | ||||
| Grade | |||||
| 1–2 | 70 (34.2) | 22 (31.4) | 0.83 | 34 (48.6) | 0.74 |
| 3 | 74 (36.0) | 22 (29.7) | 38 (51.3) | ||
| Unknown^ | 61 (29.8) | ||||
| Ki-67 | |||||
| <14 % | 26 (12.7) | 3 (11.5) | 0.05 | 12 (46.2) | 0.75 |
| ≥14 % | 127 (62.0) | 38 (29.9) | 63 (49.6) | ||
| Unknown^ | 52 (25.4) | ||||
| Molecular subclasses | |||||
| HER2+, ER+ and/or PgR+° | 125 (61.0) | 20 (16.0) | 0.001 | 51 (41.1) | 0.05 |
| HER2+, ER−, PgR−* | 80 (39.0) | 30 (37.5) | 44 (55.0) | ||
| NST duration | |||||
| ≤21 weeks | 75 (36.6) | 14 (18.7) | 0.12 | 35 (46.7) | 0.97 |
| >21 weeks | 130 (63.4) | 37 (28.5) | 61 (46.9) | ||
| Trastuzumab duration in NST | |||||
| ≤12 weeks | 104 (50.8) | 20 (19.2) | 0.06 | 45 (43.3) | 0.30 |
| >12 weeks | 101 (49.3) | 31 (30.7) | 51 (50.5) | ||
HER2 Human epidermal growth factor type 2, ER estrogen receptors, PgR progesteron receptors
^ Unknown were not included in univariate analysis, ° Luminal B/HER2+, * nonluminal/HER2+